TDACW
Translational Development Acquisition Corp.
NASDAQ · Financial Services · Financial - Conglomerates · US
$1.25
+9.65%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -72.3%
- EBIT
- -72.7%
- EPS
- -39.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- +9059.7%
- EPS
- +2384.0%
- Free cash flow
- +28.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026